SWOG clinical trial number
CTSU/R0848

A Phase III Trial Evaluating both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

Closed
Phase
Abbreviated Title
Ph III Pancreas Erlotinib and ChemoRT
Activated
12/15/2009
Closed
06/01/2018
Participants
CTSU

Research committees

Gastrointestinal Cancer
Symptom Control and Quality of Life

Treatment

5-Fluorouracil Gemcitabine hydrochloride Erlotinib Capecitabine

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

SWOG has endorsed this trial via the Endorsement Plus Option. Therefore, institutions holding dual memberships in SWOG and RTOG may credit either Group for enrollments, provided the credited investigator is a member of the credited Group.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

0.5 Cancer Control Credit

Publication Information Expand/Collapse

2020

Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial

R Abrams;K Winter;H Safran;K Goodman;W Regine;A Berger;M Gilllin;PA Philip;A Lowy;A Wu;T DePetrillo;B Corn;S Seaward;M Haddock;S Song;Y Jiang;B Fisher;A Katz;S Mehta;C Willett;C Crane American Journal of Clinical Oncology Mar;43(3):173-179

PMid: PMID31985516 | PMC number: PMC7280743

Other Clinical Trials

SWOG Clinical Trial Number
S2205

ICE COMPRESS: Randomized Trial of Limb Cryocompression versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuroropathy
Research Committee(s)
Symptom Control and Quality of Life
Activated
03/16/2023
Accrual
22%
Open
Phase
SWOG Clinical Trial Number
S2010

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence with Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
Research Committee(s)
Symptom Control and Quality of Life
Activated
01/17/2023
Accrual
64%
Open
Phase
SWOG Clinical Trial Number
EAQ202

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Research Committee(s)
Symptom Control and Quality of Life
Activated
10/28/2021
Open
Phase